A Marine Anthraquinone SZ-685C Overrides Adriamycin-Resistance in Breast Cancer Cells through Suppressing Akt Signaling

作者：Zhu, Xun; He, Zhenjian; Wu, Jueheng; Yuan, Jie; Wen, Weitao; Hu, Yiwen; Jiang, Yi; Lin, Cuiji; Zhang, Qianhui; Lin, Min; Zhang, Henan; Yang, Wan; Chen, Hong; Zhong, Lili; She, Zhigang; Chen, Shengping; Lin, Yongcheng; Li, Mengfeng^*

来源：Marine Drugs, 2012, 10(4): 694-711.

DOI：10.3390/md10040694

• SZ-685C
• breast cancer
• chemoresistance
• Akt

Breast cancer remains a major health problem worldwide. While chemotherapy represents an important therapeutic modality against breast cancer, limitations in the clinical use of chemotherapy remain formidable because of chemoresistance. The HER2/PI-3K/Akt pathway has been demonstrated to play a causal role in conferring a broad chemoresistance in breast cancer cells and thus justified to be a target for enhancing the effects of anti-breast cancer chemotherapies, such as adriamycin (ADR). Agents that can either enhance the effects of chemotherapeutics or overcome chemoresistance are urgently needed for the treatment of breast cancer. In this context, SZ-685C, an agent that has been previously shown, as such, to suppress Akt signaling, is expected to increase the efficacy of chemotherapy. Our current study investigated whether SZ-685C can override chemoresistance through inhibiting Akt signaling in human breast cancer cells. ADR-resistant cells derived from human breast cancer cell lines MCF-7, MCF-7/ADR and MCF-7/Akt, were used as models to test the effects of SZ-685C. We found that SZ-685C suppressed the Akt pathway and induced apoptosis in MCF-7/ADR and MCF-7/Akt cells that are resistant to ADR treatment, leading to antitumor effects both in vitro and in vivo. Our data suggest that use of SZ-685C might represent a potentially promising approach to the treatment of ADR-resistant breast cancer.

• 出版日期2012-4
• 单位中山大学